Intravenous immunoglobulin therapy membranous nephropathy efficacy safety Preliminary results efficacy high-dose intravenous human IgG patients biopsy-confirmed idiopathic membranous nephropathy IMGN patients normal renal function creatinine clearance BSA Group patients moderate renal insufficiency creatinine clearance BSA Group pulse doses IgG g/kg BW consecutive days boli times intervals period bolus weeks responder patients end trial new renal biopsy Group patients complete remission proteinuria daily proteinuria whereas patient partial remission proteinuria g/day Group patients complete remission partial remission patient variation proteinuria responder patients clinical biological findings nephrotic syndrome significant increase creatinine clearance control biopsies end trial immunofluorescence immunodeposits recovery glomerular lesions light microscopy conclusion IgG therapy benefit patients IMGN randomized clinical trial preliminary report 